Bacteremia Clinical Trial
Official title:
A New Antibiotic Prophylaxis Regimen to Prevent Bacteremia Following Dental Procedures
The aim of this study is to evaluate the efficacy of prophylactic dosage with amoxicillin
(AMX), amoxicillin-clavulanate (AMX-CLV), and a combination of amoxicillin-clavulanate and a
chlorhexidine mouthwash (AMX-CLV-CHX) in the prevention of bacteremia following dental
extractions.
The study hypothesis is that an antimicrobial regimen with amoxicillin-clavulanate will show
higher effectiveness in reducing the prevalence and duration of bacteremia following dental
extractions, than that achieved with the classical amoxicillin regimen.
PURPOSE: Despite the controversy about the risk of developing bacterial endocarditis of oral
origin, numerous Expert Committees in different countries continue to publish prophylactic
regimens. To date, the literature is unclear about the role of antimicrobial prophylaxis in
the prevention of bacteremia following dental procedures. The aim of this study is to
evaluate the efficacy of prophylactic dosage with amoxicillin (AMX), amoxicillin-clavulanate
(AMX-CLV), and a combination of amoxicillin-clavulanate and a CHX mouthwash (AMX-CLV-CHX) in
the prevention of bacteremia following dental extractions.
SELECTION OF THE STUDY GROUP AND STUDY DESIGN: The study group will comprise patients who,
for behavioral reasons (autism, learning disabilities, phobias, etc.), will undergo dental
extractions under general anesthesia in the Santiago de Compostela University Hospital
(Santiago de Compostela, Spain). The following exclusion criteria will be applied: age under
18 years; body weight under 40 kg; receipt of antibiotics in the previous 3 months; routine
use of oral antiseptics; a history of allergy or intolerance to AMX, CHX or AMX-CLV; any
type of congenital or acquired immunodeficiency; or any known risk factor for bacterial
endocarditis. By applying these criteria, 200 patients will be selected and will be randomly
distributed into 5 study groups: control group (receiving no prophylaxis), AMX group
(receiving 2 g AMX i.v.), AMX-CLV group (receiving 1000/200mg AMX-CLV i.v.), CHX group
(receiving a single 0.2% CHX mouthwash for 30 seconds), and AMX-CLV-CHX group (receiving
1000/200mg AMX-CLV i.v. and a single 0.2% CHX mouthwash for 30 seconds).
COLLECTION OF SAMPLES FOR BLOOD CULTURE: To determine the prevalence of bacteremia, a
peripheral venous blood sample (10 ml) will be drawn from each patient at the baseline
(before any dental manipulation but after nasotracheal intubation) and 30 s, 15 min, and 1 h
after the final dental extraction. Samples will be inoculated in BACTEC plus (Becton
Dickinson and Company, Sparks, MD) aerobic and anaerobic blood culture bottles, and will be
processed in the Bactec 9240 (Becton Dickinson).
MICROBIOLOGICAL ANALYSIS OF BLOOD CULTURES: A Gram stain will be performed on each positive
blood culture. The positive blood cultures in the aerobic media will be subcultured on blood
agar and chocolate agar in an atmosphere of 5 to 10% carbon monoxide and on MacConkey agar
under aerobic conditions. The same protocol will be used for the positive blood cultures in
the anaerobic media, with subculture on Schaedler agar and incubation in an anaerobic
atmosphere. The bacteria isolated will be identified by using the battery of biochemical
tests provided with the Vitek system for Gram-positive bacteria, Neisseria spp., Haemophilus
spp., and obligate anaerobic bacteria. The viridans group streptococci will be classified
into five groups, the Streptococcus mitis, S. anginosus, S. salivarius, S. mutans, and S.
bovis groups, by applying the Ruoff criteria. Facklam's criteria will be used to identify
unusual Streptococcus spp. and other gram-positive cocci in chains.
The subculture and further identification of the isolated bacteria will be performed by
conventional microbiological techniques. The collection, handling, and transport of the
blood samples for blood culture will be performed according to the recommendations of the
Spanish Society of Infectious Diseases and Clinical Microbiology.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03894046 -
Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
|
Phase 3 | |
| Active, not recruiting |
NCT03354338 -
Amoxicillin to Prevent Bacteria and Inflammatory Biomarkers After Intensive Periodontal Therapy
|
Phase 2 | |
| Withdrawn |
NCT02543957 -
Factors Associated With Increased Risk of Bacteremia and Cholangitis in ERCP With Cholangioscopy
|
||
| Completed |
NCT02210169 -
RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates
|
N/A | |
| Completed |
NCT01410578 -
The Value of sTREM-1, PCT, and CRP as Markers for the Detection of Sepsis and Bacteremia Among Patients With a FUO
|
N/A | |
| Terminated |
NCT00428051 -
Colombia Epidemiologic Surveillance Study
|
N/A | |
| Completed |
NCT00609375 -
Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen
|
Phase 4 | |
| Terminated |
NCT00108433 -
Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections
|
Phase 3 | |
| Completed |
NCT00177736 -
Pharmacodynamic Parameters of Two Different Doses of Cefepime
|
Phase 4 | |
| Completed |
NCT00571259 -
Prophylactic Antimicrobial Catheter Lock
|
Phase 4 | |
| Completed |
NCT00027248 -
Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections
|
Phase 3 | |
| Completed |
NCT05585463 -
Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)
|
||
| Recruiting |
NCT05950984 -
Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
|
||
| Completed |
NCT03148769 -
Spanish Bacteriemia Cohort 2016: Epidemiology, Clinical Management and Prognosis Factors
|
||
| Completed |
NCT02536352 -
Effect of Supplementation of Fluoride on Maternal Periodontal Health, Preterm Delivery, and Perinatal Well-Being
|
Early Phase 1 | |
| Completed |
NCT02869191 -
Blood Cultures's Profitability in Intensive Care Unit
|
||
| Terminated |
NCT01734694 -
Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients
|
Phase 4 | |
| Completed |
NCT01179022 -
Incidence of Bacteremia Following Argon Plasma Coagulation in Patients With Endobronchial Lesions
|
N/A | |
| Recruiting |
NCT00404625 -
Infections Caused by ESbL-Producing Enterobacteriaceae in Italy
|
N/A | |
| Completed |
NCT00398411 -
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
|
Phase 3 |